Secretion modification region-derived peptide disrupts HIV-1 Nef's interaction with mortalin and blocks virus and Nef exosome release

Journal of Virology

Volumn 86, Issue 1, 2012, Pages 406-419

  Shelton, Martin N ^a   Huang, Ming Bo ^a   Ali, Syed A ^a,b   Powell, Michael D ^a   Bond, Vincent C ^a  

^a MOREHOUSE SCHOOL OF MEDICINE   (United States)

^b ADVANCED MEDICAL AND DENTAL INSTITUTE   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MICRORNA; MORTALIN PROTEIN; NEF PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; EXOSOME; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOPRECIPITATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN TRANSPORT; TANDEM MASS SPECTROMETRY; VIRUS CELL INTERACTION; VIRUS INHIBITION; VIRUS RELEASE;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; CELL LINE; EXOSOMES; EXTRACELLULAR SPACE; HIV INFECTIONS; HIV-1; HSP70 HEAT-SHOCK PROTEINS; HUMANS; MOLECULAR SEQUENCE DATA; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; PEPTIDES; PROTEIN BINDING; PROTEIN TRANSPORT;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84855916547     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.05720-11     Document Type: Article

References (107)

1. Aiken C, Konner J, Landau NR, Lenburg ME, Trono D. 1994. Nef induces CD4 endocytosis: requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain. Cell 76:853-864.
2. Ali SA, et al. 2010. Genetic characterization of HIV type 1 Nef-induced vesicle secretion. AIDS Res. Hum. Retrovir. 26:173-192.
3. Annunziata P. 2003. Blood-brain barrier changes during invasion of the central nervous system by HIV-1. Old and new insights into the mechanism. J. Neurol. 250:901-906.
4. Badley AD, et al. 1997. Macrophage-dependent apoptosis of CD4+ T lymphocytes from HIV-infected individuals is mediated by FasL and tumor necrosis factor. J. Exp. Med. 185:55-64.
5. Bagasra O, Hauptman SP, Lischner HW, Sachs M, Pomerantz RJ. 1992. Detection of human immunodeficiency virus type 1 provirus in mononuclear cells by in situ polymerase chain reaction. N. Engl. J. Med. 326:1385-1391.
6. Berndt C, Mopps B, Angermuller S, Gierschik P, Krammer PH. 1998. CXCR4 and CD4 mediate a rapid CD95-independent cell death in CD4(+) T cells. Proc. Natl. Acad. Sci. U. S. A. 95:12556 - 12561.
7. Biberfeld P, et al. 1986. HTLV-III expression in infected lymph nodes and relevance to pathogenesis of lymphadenopathy. Am. J. Pathol. 125: 436-442.
8. Blanco J, et al. 1999. The implication of the chemokine receptor CXCR4 in HIV-1 envelope protein-induced apoptosis is independent of the G protein-mediated signalling. AIDS 13:909 - 917.
9. Brenchley JM, Price DA, Douek DC. 2006. HIV disease: fallout from a mucosal catastrophe? Nat. Immunol. 7:235-239.
10. Bresnahan PA, et al. 1998. A dileucine motif in HIV-1 Nef acts as an internalization signal for CD4 downregulation and binds the AP-1 clathrin adaptor. Curr. Biol. 8:1235-1238.
11. Calenda V, Graber P, Delamarter JF, Chermann JC. 1994. Involvement of HIV nef protein in abnormal hematopoiesis in AIDS: in vitro study on bone marrow progenitor cells. Eur. J. Haematol. 52:103-107.
12. Campbell TD, Khan M, Huang MB, Bond VC, Powell MD. 2008. HIV-1 Nef protein is secreted into vesicles that can fuse with target cells and virions. Ethn. Dis. 18:S2-S9.
13. Carbonari M, et al. 1997. Death of bystander cells by a novel pathway involving early mitochondrial damage in human immunodeficiency virus-related lymphadenopathy. Blood 90:209 - 216.
14. Casartelli N, et al. 2006. The Pro78 residue regulates the capacity of the human immunodeficiency virus type 1 Nef protein to inhibit recycling of major histocompatibility complex class I molecules in an SH3-independent manner. J. Gen. Virol. 87:2291-2296.
15. Choi DS, et al. 2007. Proteomic analysis of microvesicles derived from human colorectal cancer cells. J. Proteome Res. 6:4646-4655.
16. Clerici M, et al. 1996. Antigen-stimulated apoptotic T-cell death in HIV infection is selective for CD4+ T cells, modulated by cytokines and effected by lymphotoxin. AIDS 10:603-611.
17. Clerici M, et al. 1994. Type 1/type 2 cytokine modulation of T-cell programmed cell death as a model for human immunodeficiency virus pathogenesis. Proc. Natl. Acad. Sci. U. S. A. 91:11811-11815.
18. Craig HM, Pandori MW, Guatelli JC. 1998. Interaction of HIV-1 Nef with the cellular dileucine-based sorting pathway is required for CD4 down-regulation and optimal viral infectivity. Proc. Natl. Acad. Sci. U. S. A. 95:11229 - 11234.
19. Deacon NJ, et al. 1995. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 270: 988-991.
20. Dickie P. 1996. HIV type 1 Nef perturbs eye lens development in transgenic mice. AIDS Res. Hum. Retrovir. 12:177-189.
21. Dickie P. 2000. Nef modulation of HIV type 1 gene expression and cytopathicity in tissues of HIV transgenic mice. AIDS Res. Hum. Retrovir. 16:777-790.
22. Dickie P, Ramsdell F, Notkins AL, Venkatesan S. 1993. Spontaneous and inducible epidermal hyperplasia in transgenic mice expressing HIV-1 Nef. Virology 197:431-438.
23. Domanico SZ, DeNagel DC, Dahlseid JN, Green JM, Pierce SK. 1993. Cloning of the gene encoding peptide-binding protein 74 shows that it is a new member of the heat shock protein 70 family. Mol. Cell. Biol. 13: 3598-3610.
24. Fackler OT, Luo W, Geyer M, Alberts AS, Peterlin BM. 1999. Activation of Vav by Nef induces cytoskeletal rearrangements and downstream effector functions. Mol. Cell 3:729 - 739.
25. Federico M, et al. 2001. HIV-1 Nef activates STAT1 in human monocytes/macrophages through the release of soluble factors. Blood 98:2752-2761.
26. Fevrier B, Raposo G. 2004. Exosomes: endosomal-derived vesicles shipping extracellular messages. Curr. Opin. Cell Biol. 16:415-421.
27. Finkel TH, et al. 1995. Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nat. Med. 1:129 - 134.
28. Fonseca SB, Pereira MP, Kelley SO. 2009. Recent advances in the use of cell-penetrating peptides for medical and biological applications. Adv. Drug Deliv. Rev. 61:953-964.
29. Fujii Y, Otake K, Tashiro M, Adachi A. 1996. Human immunodeficiency virus type 1 Nef protein on the cell surface is cytocidal for human CD4+ T cells. FEBS Lett. 393:105-108.
30. Fujii Y, Otake K, Tashiro M, Adachi A. 1996. Soluble Nef antigen of HIV-1 is cytotoxic for human CD4+ T cells. FEBS Lett. 393:93-96.
31. Geleziunas R, Xu W, Takeda K, Ichijo H, Greene WC. 2001. HIV-1 Nef inhibits ASK1-dependent death signalling providing a potential mechanism for protecting the infected host cell. Nature 410:834-838.
32. Geyer M, Fackler OT, Peterlin BM. 2001. Structure-function relationships in HIV-1 Nef. EMBO Rep. 2:580 - 585.
33. Giorgi JV, et al. 1999. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J. Infect. Dis. 179:859-870.
34. Gougeon ML, et al. 1996. Programmed cell death in peripheral lymphocytes from HIV-infected persons: increased susceptibility to apoptosis of CD4 and CD8 T cells correlates with lymphocyte activation and with disease progression. J. Immunol. 156:3509 - 3520.
35. Gratton S, Cheynier R, Dumaurier MJ, Oksenhendler E, Wain-Hobson S. 2000. Highly restricted spread of HIV-1 and multiply infected cells within splenic germinal centers. Proc. Natl. Acad. Sci. U. S. A. 97:14566 - 14571.
36. Greenberg ML, Cammack N. 2004. Resistance to enfuvirtide, the first HIV fusion inhibitor. J. Antimicrob. Chemother. 54:333-340.
37. Greenway AL, et al. 2002. Human immunodeficiency virus type 1 Nef binds to tumor suppressor p53 and protects cells against p53-mediated apoptosis. J. Virol. 76:2692-2702.
38. Grzesiek S, Stahl SJ, Wingfield PT, Bax A. 1996. The CD4 determinant for downregulation by HIV-1 Nef directly binds to Nef. Mapping of the Nef binding surface by NMR. Biochemistry 35:10256 - 10261.
39. Hanna Z, et al. 1998. Nef harbors a major determinant of pathogenicity for an AIDS-like disease induced by HIV-1 in transgenic mice. Cell 95: 163-175.
40. Hanna Z, et al. 2001. The pathogenicity of human immunodeficiency virus (HIV) type 1 Nef in CD4C/HIV transgenic mice is abolished by mutation of its SH3-binding domain, and disease development is delayed in the absence of Hck. J. Virol. 75:9378 - 9392.
41. Herbein G, Van Lint C, Lovett JL, Verdin E. 1998. Distinct mechanisms trigger apoptosis in human immunodeficiency virus type 1-infected and in uninfected bystander T lymphocytes. J. Virol. 72:660-670.
42. Ho DD, et al. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126.
43. Huang MB, Hunter M, Bond VC. 1999. Effect of extracellular human immunodeficiency virus type 1 glycoprotein 120 on primary human vascular endothelial cell cultures. AIDS Res. Hum. Retrovir. 15:1265-1277.
44. Huang MB, et al. 2004. Characterization of Nef-CXCR4 interactions important for apoptosis induction. J. Virol. 78:11084-11096.
45. Iosefson O, Azem A. 2010. Reconstitution of the mitochondrial Hsp70 (mortalin)-p53 interaction using purified proteins: identification of additional interacting regions. FEBS Lett. 584:1080-1084.
46. James CO, et al. 2004. Extracellular Nef protein targets CD4+T cells for apoptosis by interacting with CXCR4 surface receptors. J. Virol. 78: 3099-3109.
47. Jekle A, et al. 2003. In vivo evolution of human immunodeficiency virus type 1 toward increased pathogenicity through CXCR4-mediated killing of uninfected CD4 T cells. J. Virol. 77:5846-5854.
48. Kajiyama W, Kopp JB, Marinos NJ, Klotman PE, Dickie P. 2000. Glomerulosclerosis and viral gene expression in HIV-transgenic mice: role of nef. Kidney Int. 58:1148 - 1159.
49. Kanai M, et al. 2007. Physical and functional interaction between mortalin and Mps1 kinase. Genes Cells 12:797-810.
50. Kaul SC, Aida S, Yaguchi T, Kaur K, Wadhwa R. 2005. Activation of wild type p53 function by its mortalin-binding, cytoplasmically localizing carboxyl terminus peptides. J. Biol. Chem. 280:39373-39379.
51. Kaul SC, Taira K, Pereira-Smith OM, Wadhwa R. 2002. Mortalin: present and prospective. Exp. Gerontol. 37:1157-1164.
52. Kay DG, et al. 2002. Cardiac disease in transgenic mice expressing human immunodeficiency virus-1 nef in cells of the immune system. Am. J. Pathol. 161:321-335.
53. Kestler HW, et al. 1991. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 65:651-662.
54. Khan M, Garcia-Barrio M, Powell MD. 2001. Restoration of wild-type infectivity to human immunodeficiency virus type 1 strains lacking nef by intravirion reverse transcription. J. Virol. 75:12081-12087.
55. Kim KB, et al. 2006. Oxidation-reduction respiratory chains and ATP synthase complex are localized in detergent-resistant lipid rafts. Proteomics 6:2444 - 2453.
56. Kim SY, Byrn R, Groopman J, Baltimore D. 1989. Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression. J. Virol. 63: 3708-3713.
57. Kirchhoff F, Greenough TC, Brettler DB, Sullivan JL, Desrosiers RC. 1995. Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N. Engl. J. Med. 332:228 - 232.
58. Lagaudriere-Gesbert C, Newmyer SL, Gregers TF, Bakke O, Ploegh HL. 2002. Uncoating ATPase Hsc70 is recruited by invariant chain and controls the size of endocytic compartments. Proc. Natl. Acad. Sci. U. S. A. 99:1515-1520.
59. Laguette N, Bregnard C, Benichou S, Basmaciogullari S. 2010. Human immunodeficiency virus (HIV) type-1, HIV-2 and simian immunodeficiency virus Nef proteins. Mol. Aspects Med. 31:418-433.
60. Lakey EK, Margoliash E, Pierce SK. 1987. Identification of a peptide binding protein that plays a role in antigen presentation. Proc. Natl. Acad. Sci. U. S. A. 84:1659 - 1663.
61. Learmont JC, et al. 1999. Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort. N. Engl. J. Med. 340:1715-1722.
62. Ledru E, Lecoeur H, Garcia S, Debord T, Gougeon ML. 1998. Differential susceptibility to activation-induced apoptosis among peripheral Th1 subsets: correlation with Bcl-2 expression and consequences for AIDS pathogenesis. J. Immunol. 160:3194-3206.
63. Lenassi M, et al. 2009. HIV Nef is secreted in exosomes and triggers apoptosis in bystander CD4 T cells. Traffic 11:110-122.
64. Li G, et al. 1997. Rapid mass spectrometric identification of proteins from two-dimensional polyacrylamide gels after in gel proteolytic digestion. Electrophoresis 18:391-402.
65. Ma Z, et al. 2006. Mortalin controls centrosome duplication via modulating centrosomal localization of p53. Oncogene 25:5377-5390.
66. Martin-Serrano J, Zang T, Bieniasz PD. 2003. Role of ESCRT-I in retroviral budding. J. Virol. 77:4794-4804.
67. McCloskey TW, et al. 1997. Dual role of HIV Tat in regulation of apoptosis in T cells. J. Immunol. 158:1014 - 1019.
68. McCune JM. 2001. The dynamics of CD4+ T-cell depletion in HIV disease. Nature 410:974 - 979.
69. Medzihradszky KF, et al. 2000. The characteristics of peptide collisioninduced dissociation using a high-performance MALDI-TOF/TOF tandem mass spectrometer. Anal. Chem. 72:552-558.
70. Miura Y, et al. 2001. Critical contribution of tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL) to apoptosis of human CD4+T cells in HIV-1-infected hu-PBL-NOD-SCID mice. J. Exp. Med. 193:651-660.
71. Mizukoshi E, et al. 1999. Fibroblast growth factor-1 interacts with the glucose-regulated protein GRP75/mortalin 4. J. 343:461-466.
72. Muratori C, et al. 2009. Massive secretion by T cells is caused by HIV Nef in infected cells and by Nef transfer to bystander cells. Cell Host Microbe 6:218 - 230.
73. Niederman TM, Hastings WR, Ratner L. 1993. Myristoylationenhanced binding of the HIV-1 Nef protein to T cell skeletal matrix. Virology 197:420-425.
74. Otvos L, Jr. 2008. Peptide-based drug design: here and now. Methods Mol. Biol. 494:1-8.
75. Peddibhotla S, Lam MH, Gonzalez-Rimbau M, Rosen JM. 2009. The DNA-damage effector checkpoint kinase 1 is essential for chromosome segregation and cytokinesis. Proc. Natl. Acad. Sci. U. S. A. 106: 5159-5164.
76. Percario Z, et al. 2003. Human immunodeficiency virus type 1 (HIV-1) Nef activates STAT3 in primary human monocyte/macrophages through the release of soluble factors: involvement of Nef domains interacting with the cell endocytotic machinery. J. Leukoc. Biol. 74:821-832.
77. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. 1996. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271:1582-1586.
78. Perkins DN, Pappin DJ, Creasy DM, Cottrell JS. 1999. Probabilitybased protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 20:3551-3567.
79. Piguet V, et al. 2000. HIV-1 Nef protein binds to the cellular protein PACS-1 to downregulate class I major histocompatibility complexes. Nat. Cell Biol. 2:163-167.
80. Pilzer D, Fishelson Z. 2005. Mortalin/GRP75 promotes release of membrane vesicles from immune attacked cells and protection from complement-mediated lysis. Int. Immunol. 17:1239-1248.
81. Pilzer D, Saar M, Koya K, Fishelson Z. 2009. Mortalin inhibitors sensitize K562 leukemia cells to complement-dependent cytotoxicity. Int. J. Cancer 126:1428- 1435.
82. Qi M, Aiken C. 2008. Nef enhances HIV-1 infectivity via association with the virus assembly complex. Virology 373:287-297.
83. Raymond AD, et al. 2011. HIV type 1 Nef is released from infected cells in CD45(+) microvesicles and is present in the plasma of HIV-infected individuals. AIDS Res. Hum. Retrovir. 27:167-178.
84. Rodriguez B, et al. 2006. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA 296: 1498-1506.
85. Sahu R, et al. 2011. Microautophagy of cytosolic proteins by late endosomes. Dev. Cell 20:131-139.
86. Saksela K, Cheng G, Baltimore D. 1995. Proline-rich (PxxP) motifs in HIV-1 Nef bind to SH3 domains of a subset of Src kinases and are required for the enhanced growth of Nef+ viruses but not for downregulation of CD4. EMBO J. 14:484-491.
87. Salvi R, et al. 1998. Grossly defective nef gene sequences in a human immunodeficiency virus type 1-seropositive long-term nonprogressor. J. Virol. 72:3646 - 3657.
88. Sanfridson A, Hester S, Doyle C. 1997. Nef proteins encoded by human and simian immunodeficiency viruses induce the accumulation of endosomes and lysosomes in human T cells. Proc. Natl. Acad. Sci. U. S. A. 94:873-878.
89. Shin BK, et al. 2003. Global profiling of the cell surface proteome of cancer cells uncovers an abundance of proteins with chaperone function. J. Biol. Chem. 278:7607-7616.
90. Shugars DC, et al. 1993. Analysis of human immunodeficiency virus type 1 nef gene sequences present in vivo. J. Virol. 67:4639-4650. (Erratum, 68:5335, 1994.)
91. Simard MC, et al. 2002. Expression of simian immunodeficiency virus nef in immune cells of transgenic mice leads to a severe AIDS-like disease. J. Virol. 76:3981-3995.
92. Simmonds P, et al. 1990. Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers. J. Virol. 64:864-872.
93. Singh B, et al. 1997. Cloning and some novel characteristics of mitochondrial Hsp70 from Chinese hamster cells. Exp. Cell Res. 234:205-216.
94. Skowronski J, Parks D, Mariani R. 1993. Altered T cell activation and development in transgenic mice expressing the HIV-1 nef gene.EMBOJ. 12:703-713.
95. Staubach S, Razawi H, Hanisch FG. 2009. Proteomics of MUC1-containing lipid rafts from plasma membranes and exosomes of human breast carcinoma cells MCF-7. Proteomics 9:2820-2835.
96. Taylor DD, Akyol S, Gercel-Taylor C. 2006. Pregnancy-associated exosomes and their modulation of T cell signaling. J. Immunol. 176: 1534-1542.
97. Vanbuskirk A, Crump BL, Margoliash E, Pierce SK. 1989. A peptide binding protein having a role in antigen presentation is a member of the HSP70 heat shock family. J. Exp. Med. 170:1799-1809.
98. VanBuskirk AM, DeNagel DC, Guagliardi LE, Brodsky FM, Pierce SK. 1991. Cellular and subcellular distribution of PBP72/74, a peptidebinding protein that plays a role in antigen processing. J. Immunol. 146: 500-506.
99. Varin A, et al. 2003. Exogenous Nef protein activates NF-kappa B, AP-1, and c-Jun N-terminal kinase and stimulates HIV transcription in promonocytic cells. Role in AIDS pathogenesis. J. Biol. Chem. 278: 2219-2227.
100. Vlahakis SR, et al. 2001. Chemokine-receptor activation by env determines the mechanism of death in HIV-infected and uninfected T lymphocytes. J. Clin. Invest. 107:207-215.
101. von Schwedler UK, et al. 2003. The protein network of HIV budding. Cell 114:701-713.
102. Wadhwa R, et al. 2006. Upregulation of mortalin/mthsp70/Grp75 contributes to human carcinogenesis. Int. J. Cancer 118:2973-2980.
103. Walker C, Bottger S, Low B. 2006. Mortalin-based cytoplasmic sequestration of p53 in a nonmammalian cancer model. Am. J. Pathol. 168: 1526-1530.
104. Wei X, et al. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117-122.
105. Wittrup A, et al. 2010. Magnetic nanoparticle-based isolation of endocytic vesicles reveals a role of the heat shock protein GRP75 in macromolecular delivery. Proc. Natl. Acad. Sci. U. S. A. 107:13342-13347.
106. Yu S, et al. 2007. Tumor exosomes inhibit differentiation of bone marrow dendritic cells. J. Immunol. 178:6867-6875.
107. Zhang M, et al. 2001. Identification of a potential HIV-induced source of bystander-mediated apoptosis in T cells: upregulation of trail in primary human macrophages by HIV-1 tat. J. Biomed. Sci. 8:290-296.